Tobramycin Sulfate Injection shortage
To Be Discontinued 1 presentations · 1 manufacturers · first FDA posting 2026-07-17 · last update 2026-07-17
Manufacturers: Hospira, Inc., a Pfizer Company
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Tobramycin Sulfate, Injection, 80 mg/2 mL (40 mg/mL); 2 mL Multiple Dose Glass Fliptop Vial (NDC 0409-3578-01) | Hospira, Inc., a Pfizer Company | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 07/17/2026 Updated 07/17/2026 Discontinued 07/17/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)